13 marzo 2015
DT2219, a new bispecific ligand-directed diphtheria toxin, was found to be safe and clinically effective in a small group of patients with relapsed/refractory B-cell malignancies, according to phase I clinical trial data.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/rW-jFpakIew/150313083621.htm
